AptarGroup acquires Mod3 Pharma's clinical trial manufacturing capabilities
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
an hour ago
- Fast Company
Don't drink this recalled instant coffee from Dollar General. It might contain something dangerous
Of all the things you don't want to find in a jar of instant coffee, glass is pretty high on the list. But that scenario became more than hypothetical after a customer alerted Dollar General employees to a 'potential issue' in their eight-ounce instant coffee. Now, Dollar General has issued a recall of three lots of the powdered drink due to the possibility of glass fragments. The recall impacts retailer's private label brand Clover Valley. 'Dollar General is actively investigating the source of the glass contamination and apologizes for any inconvenience caused by this product issue,' the chain said in a statement. The recall was also announced by the Food and Drug Administration (FDA). Here's everything you need to know about identifying the affected items. Which products are affected? The recalled coffee is the Clover Valley brand's eight-ounce instant coffee. It has a package UPC of 876941004069 and includes the following three lots: L-5163: Best by December 13, 2026 L-5164: Best by December 13, 2026 L-5165: Best by December 14, 2026 You can find this information on the neck of the jar. An image of the product can be found on the FDA's website. Where and when was the product sold? The coffee was exclusively sold in Dollar General retail stores between July 9 and 21, 2025, and across almost every state. Here's a complete list of the states where Dollar General has recalled its eight-ounce Clover Valley Instant Coffee: Alabama Arkansas Arizona California Colorado Connecticut Delaware Florida Georgia Iowa Idaho Illinois Indiana Kansas Kentucky Louisiana Massachusetts Maryland Maine Michigan Minnesota Missouri Mississippi Montana North Carolina North Dakota Nebraska New Hampshire New Jersey New Mexico Nevada New York Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Virginia Vermont Washington Wisconsin West Virginia Wyoming If your imagination isn't detailed enough, Dollar General provides a graphic breakdown in its announcement of what can happen if you ingest glass. (We'll leave reading that to your discretion.) The company says it hasn't received any reports of injuries or illnesses. What should I do if I have this product? Don't drink it. Dollar General is offering a refund for anyone who bought the instant coffee. You can reach out for one through email at customercare@ The company can also process a refund over the phone every day from 6 a.m. to 1 a.m. at 1-888-309-9030.
Yahoo
an hour ago
- Yahoo
Abbott Taps Growing TMVR Market With Tendyne System
Abbott Laboratories ABT recently received Food and Drug Administration ('FDA') approval for its Tendyne transcatheter mitral valve replacement (TMVR) system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification (MAC). The Tendyne system expands the company's comprehensive Structural Heart portfolio. The rising prevalence of mitral valve diseases, growing preferences for minimally invasive procedures and expanding geriatric population has driven the adoption of TMVR system. Investors are eyeing this fast-growing market, which is projected to witness a compound annual growth rate of 20% from 2025 to 2030 (Per a Medi-Tech Insights report). MAC stiffens the structure of the mitral valve and can lead to mitral regurgitation or stenosis that disrupts the heart's ability to pump blood effectively. The complex nature of this mitral valve disease and patients' specific needs and health conditions can pose challenges for surgical correction. The Tendyne system offers an alternative, minimally invasive way to replace the valve of patients with severe MAC who are at high risk for open-heart surgery. The innovative and unique design of the Tendyne system and the valve's availability in multiple sizes allow it to adapt to a range of patient anatomies. The self-expanding valve is delivered through a small incision in the chest and then advanced into the heart to replace the mitral valve. The valve is fully repositionable and retrievable during implantation, allowing for the best possible outcome for people requiring a valve replacement. Offerings By ABT's Peers in the Structural Heart Field Edwards Lifesciences EW makes significant investments in the development of transcatheter heart valve repair and replacement technologies designed to treat mitral and tricuspid valve diseases. The company's PASCAL Precision system addresses the needs of patients with mitral or tricuspid regurgitation through leaflet approximation. The EVOQUE system is the world's first transcatheter tricuspid valve replacement therapy to receive regulatory approval. It addresses tricuspid valve regurgitation by replacing the native valve with a bioprosthetic valve. In addition, SAPIEN M3 transcatheter mitral valve replacement system is designed specifically for patients with symptomatic mitral regurgitation. Medtronic's MDT Structural Heart & Aortic division offers therapies for heart valve disorders and aortic disease. Key products include the CoreValve family (Evolut PRO, PRO+, FX, FX+ TAVR systems), surgical valve replacement and repair solutions (tissue and mechanical), blood-handling systems, surgical ablation technologies, and positioning/stabilization tools. The company also provides endovascular stent grafts and accessories like the Endurant II Stent Graft System (abdominal aortic aneurysms), Valiant Captivia Thoracic Stent Graft System (thoracic repair) and Heli-FX EndoAnchor System. ABT Price Performance In the past year, Abbott shares have surged 19.2%, outperforming the industry's 6.2% growth. The S&P 500 composite grew 17.8% in the same period. Image Source: Zacks Investment Research Discounted Valuation ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 4.87X compared with the industry average of 5.56X. Image Source: Zacks Investment Research ABT Stock Estimate Trend In the past 30 days, Tempus AI's EPS estimate has moved south 0.2% for 2025. Image Source: Zacks Investment Research ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is one of the . A definitive merger agreement announced in the first week of August drives a short-term surge in the stocks' performance. A scientist in a lab coat, holding a beaker of a biopharmaceutical creation. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based oncology treatments. The company's lead product, DANYELZA® (naxitamab-gqgk), is the first FDA-approved therapy for relapsed or refractory high-risk neuroblastoma in bone or bone marrow. Operating from New Jersey, the company also advances a robust pipeline of investigational cancer therapies. On August 5, 2025, SERB Pharmaceuticals agreed to acquire Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) in an all-cash transaction valued at approximately $412 million. SERB will commence a tender offer to purchase all outstanding shares of the company's common stock for $8.60 per share in cash. This offer represents an approximate 105% premium to Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)' closing share price on August 4, 2025, the last full trading day before the transaction announcement. The acquisition includes DANYELZA, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)' lead commercial oncology asset. SERB intends to use it for broadening its existing Rare Oncology portfolio and expanding its investment in the U.S. market. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)'s stock price soared by 71.43% this week, gaining a dramatic rebound after a 26.80% yearly drop, making it one of the best short-term biotech investments. While we acknowledge the potential of YMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
